Following on from information provided to NICE by the company in January 2020, the appraisal of Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1674 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2020, the appraisal of Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 29 January 2020 | Suspended. Topic is suspended |
| 29 January 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. Please note that following on from advice received from the company regarding the regulatory timelines , NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 02 October 2019 - 30 October 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 31 July 2017 | In progress. DHSC Referral Received |
For further information on our processes and methods, please see our CHTE processes and methods manual